Denali: Despite ALS Primary Endpoint Failure, Possible Path Forward Remains
Denali Therapeutics Inc.'s stock remains stable despite trial setback in ALS. BLA filing for MPS II treatment on track. Click ...
ALS News Today10h
Revisiting the past is bittersweet when living with ALS
In her husband's nearly 15 years of living with ALS, columnist Kristin Neva sees pre- and post-diagnosis papers as a bittersweet treasure.
ALS News Today12h
DNL343, fosigotifator fail HEALEY platform trial’s main goal in ALS
DNL343 and fosigotifator are made to activate the ISR pathway protein eIF2B, but both failed to slow ALS progression in the HEALEY trial.
Santa Rosa Press Democrat1d
ALS sidelined this Israeli TV journalist. AI is helping him make a comeback.
A renowned Israeli TV journalist who lost his ability to speak clearly because of ALS is returning to the air using artificial-intelligence software that recreates his widely recognized gravelly voice ...
FierceBiotech2d
Rival AbbVie and Denali prospects flunk phase 2/3 ALS tests, denting hopes for shared mechanism
AbbVie, Calico and Denali Therapeutics’ hopes of treating amyotrophic lateral sclerosis (ALS) by targeting eIF2B have all ...
Rolling Out6d
The truth behind muscle twitches and their real meaning
Think muscle twitches are harmless? Think again. Discover the hidden health risks and learn when to take action.